
The recent FDA approvals for donanemab (Kinsunla®) and lecanemab (Leqembi®) for the treatment of Alzheimer’s mark a major step forward for dementia research. While these treatments focus on Alzheimer’s, they offer hope for Parkinson’s disease as well.
… Full Story>